Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study

Figure 1 Kaplan-Meier curves comparing survival outcomes between groups. A: Estimated survival without variceal rebleeding in Group A [direct-acting antiviral (DAA)-treated] and Group B (non-DAA-treated) over time, showing a significantly lower rebleeding rate in Group A (log-rank P < 0.001); B: Overall survival in both groups, demonstrating a significant survival benefit for the DAA-treated group (log-rank P = 0.012). DAA: Direct-acting antiviral.